This newsletter will shed light upon following key aspects :
•    High cumulative incidence of thrombotic complications in critically-ill patients with COVID-19 pneumonia
•    Anticoagulant therapy mainly with LMWH and its association with decreased mortality in severe COVID-19 patients with coagulopathy
•    Recommendation of anticoagulant thromboprophylaxis with LMWH or UFH in critically ill patients with COVID-19 over fondaparinux or DOAC